A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and Imatinib Combination to Eliminate Stem cells) was an international, randomised phase II trial designed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmieder, S., BrÜmmendorf, T. H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., Nicolini, F. E., Holyoake, T. L., Copland, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224085/
https://www.ncbi.nlm.nih.gov/pubmed/31925317
http://dx.doi.org/10.1038/s41375-019-0700-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224085/
https://www.ncbi.nlm.nih.gov/pubmed/31925317
http://dx.doi.org/10.1038/s41375-019-0700-9

Ejemplares similares